ONCY ONCOLYTICS BIOTECH INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1129928 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-639.3%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets228.7%
Debt / equity—
Current ratio0.89x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.77x
Accruals ratio-145.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | — | — | — | — | — | — | — |
| R&D expense | $5.15M | $4.26M | $4.55M | $3.52M | $5.08M | $1.92M | $2.80M |
| SG&A expense | $4.59M | $5.12M | $4.73M | $5.97M | $4.48M | $2.73M | $2.22M |
| Operating income | -$9.74M | -$9.38M | -$9.28M | -$9.49M | -$9.56M | -$4.65M | -$5.02M |
| Pretax income | -$9.72M | -$9.34M | — | -$8.69M | -$10.06M | -$5.22M | — |
| Income tax | -$13,000 | $101,000 | — | $199,000 | -$181,000 | $61,000 | — |
| Net income | -$9.71M | -$9.44M | -$9.24M | -$8.89M | -$9.88M | -$5.28M | -$4.71M |
| EBITDA | -$9.72M | -$9.36M | -$9.27M | -$9.47M | -$9.55M | -$4.63M | -$5.00M |
| EPS (basic) | -0.08 | -0.08 | -0.08 | — | -0.10 | -0.06 | -0.06 |
| EPS (diluted) | -0.08 | -0.08 | -0.08 | — | -0.10 | -0.06 | -0.06 |
| Weighted avg. shares (diluted) | 127.89M | 119.74M | 112.29M | — | 101.32M | 91.00M | 84.63M |
| Balance sheet | |||||||
| Cash & equivalents | $2.43M | $4.12M | $5.49M | $5.20M | $8.87M | $10.72M | $10.64M |
| Current assets | $5.27M | $7.07M | $7.49M | $6.84M | — | — | — |
| PP&E, net | $193,000 | $202,000 | $218,000 | $228,000 | — | — | — |
| Total assets | $5.83M | $7.67M | $8.16M | $7.58M | — | — | — |
| Current liabilities | $5.92M | $5.22M | $5.42M | $6.10M | — | — | — |
| Total liabilities | $13.34M | $13.84M | $13.29M | $11.38M | — | — | — |
| Shareholders' equity | -$7.50M | -$6.17M | -$5.13M | -$3.80M | -$272,000 | $3.70M | $3.73M |
| Shares outstanding | 132.21M | 124.64M | 116.13M | 108.02M | — | — | — |
| Cash flow statement | |||||||
| Operating cash flow | -$6.92M | -$8.14M | -$7.29M | -$6.43M | -$4.84M | -$4.11M | -$4.73M |
| Capital expenditure | $7,000 | $0 | $6,000 | $1,000 | $4,000 | $0 | $1,000 |
| Free cash flow | -$6.92M | -$8.14M | -$7.30M | -$6.43M | -$4.85M | -$4.11M | -$4.73M |
| Investing cash flow | -$7,000 | $0 | -$6,000 | -$1,000 | -$4,000 | $0 | -$1,000 |
| Financing cash flow | $5.24M | $6.77M | $7.61M | $2.75M | $3.09M | $4.09M | $4.18M |
| Depreciation & amortization | $17,000 | $15,000 | $16,000 | $16,000 | $17,000 | $18,000 | $19,000 |
| Stock-based compensation | $2.03M | $2.44M | $2.30M | $985,000 | $2.57M | $362,000 | $845,000 |
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.